1 active not recruiting, 1 completed, 1 unknown. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Microbiotica Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis MB310, Placebo, Vancomycin - Ulcerative Colitis | Phase 1 | Completed | Microbiotica Ltd | 29 | 2024-09-27 | 2026-06-15 |
| A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients MB097, Pembrolizumab, Vancomycin - Melanoma | Phase 1 | Active not recruiting | Microbiotica Ltd | 41 | 2024-08-28 | 2025-09-26 |
| Microbiome Immunotherapy Toxicity and Response Evaluation Nivolumab, Pembrolizumab, Ipilimumab - Melanoma, Renal Cancer | Unknown | CCTU- Cancer Theme | 1800 | 2020-07-08 | 2023-02-16 |
Melanoma (2) · Colitis, Ulcerative (1) · Kidney Neoplasms (1) · Lung Neoplasms (1)
Vancomycin (2) · pembrolizumab (2) · Bevacizumab (1) · Ipilimumab (1) · Nivolumab (1) · atezolizumab (1) · durvalumab (1) · tremelimumab (1)
United Kingdom (3) · Spain (2) · Austria (1) · Bulgaria (1) · France (1) · Italy (1) · Poland (1)
Pippa Corrie (1)
2023 (2)